Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy

 
• By Jung Won Shin

The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.

Pricing Strategy
ViroMed Lays Out Gene Therapy Strategy • Source: Shutterstock

More from South Korea

More from Focus On Asia